Only about 30% of patients with abdominal metastasis of gastric adenocarcinoma are cured after standardized treatment; some late-stage patients cannot be cured by radical treatment of the tumor, but systemic chemotherapy and local radiotherapy can be used to prolong the survival period of the patients. Gastric adenocarcinoma is a malignant tumor of digestive system caused by Helicobacter pylori and hereditary factors. With the progress of the disease, distant metastasis, such as abdominal implantation metastasis, can appear in the late stage, which may cause malignant ascites, abdominal pain, abdominal distension and other clinical manifestations. The primary and metastatic foci are mostly treated by non-surgical therapies such as radiotherapy and chemotherapy; symptomatic treatment can also be carried out by extracting ascites through peritoneal puncture and taking diuretics such as hydrochlorothiazide as prescribed by doctors. After active treatment, the main purpose is to prolong the survival period and improve the quality of life of patients. Gastric adenocarcinoma should seek medical treatment as early as possible and standardize the treatment under the guidance of professional doctors to avoid delaying the condition.